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Abstract 
 
The aim of this research was to enhance the flux of transdermal drug 
delivery by using penetration enhancers DMSO. Skin penetration 
enhancers have been used to improve bioavailability and increase the 
range of drugs for which topical and transdermal delivery is a viable 
option which penetrate into skin to reversibly decrease the barrier 
resistance. Penetration enhancing activity of dimethylsulphoxide 
(DMSO) at 5% w/w and 10% w/w concentration were determined in 
aqueous solution of ACV and in microemulsion formulations though 
calculation of transdermal flux of ACV with Keshary Chein Frenz 
Diffusion cell by using wistar albino rat skin. The transdermal flux 
of formulations PD, PD5D, PD10D, ME1 and ME10D was found to 
be 2.47, 50.7529, 119.7691, 238.1432 and 266.6721µg/cm2/h. The 
flux of microemulsion formulation ME10D was found 266.6721± 
8.49 µg/cm2/h. Which showed highest value and skin flux of the 
drug could be enhanced up to 107 fold compared to its aqueous 
solution by preparing microemulsion ME10D. DMSO in 
microemulsion formulation is safe to the skin at 10% DMSO w/w. 
Keywords: DMSO, Penetration enhancer, Ethanol, Transdermal 
Microemulsion, Acyclovir (ACV)  
 
Introduction 
The improvement of drug permeability though 
the skin is always a difficult problem because of 
barriers function of human skin epithelia to 
exogenous substances. Therefore, the major 
challenge in topical administration is to increase 
the drug penetration into the skin moreover the 
most of the pharmaceutical substances are 
lipophilic in nature. The clinical efficacy of such 
drugs is being impeded by their low aqueous 
solubility resulting in poor penetration and 
absorption mainly when they are designed for 
transdermal administration. Skin is a remarkably 
efficient barrier, designed to keep ‘‘our insides in 
and the outsides out’’. This barrier property 
causes difficulties for transdermal delivery of 
therapeutic agents. One long-standing approach 
to increase the range of drugs that can be 
effectively delivered via this route has been to 
use penetration enhancers [1]. The use of a 
microemulsion  as vehicle may enhance 
transdermal penetration by various mechanism, 
many molecules or solubilized in microemulsion 
in addition microemulsion induce a change in the 
thermodynamic activity of the  drug they  
contain, modifying their partition coefficient and 
thus favour penetration of the stratum corneum. 
Furthermore, their component surfactant reduces 
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the functional barrier of stratum corneum. This 
latter function may be more or less important 
depending on the nature of the surfactant used 
[2]. 
In principle, microemulsion and its gel can be 
used to deliver drug to the patient via several 
routes, but the transdermal application of 
microemulsion has gained increasing interest. 
Microemulsion gel has improved the transdermal 
delivery of several drugs over the conventional 
preparation such as emulsion [3, 4]. 
Microemulsion 
Microemulsion is defined as thermodynamically 
stable   transparent, single optically isotropic 
liquid system of water oil and surfactants 
frequently in combination with suitable 
cosurfactants [5, 6]. The concept of micro-
emulsion was fit introduced by Hoar and 
Schulman in 1940 [7] and the term 
microemulsion was first carried by schulman and 
coworkers in 1959 to described the clear fluid 
systems obtained by titration to the point of 
clarity of an ordinary milky emulsion 
(macroemulsion) by the addition of a medium 
chain alcohol such as pentanol and hexanol. The 
droplet size (100-600 nm) was much hence their 
transparent appearances and the adoption of the 
term microemulsion according to Schulman [8]. 
But according to some other scientist the 
microemulsion droplet size lies in the range of 
10- 100nm Jang et al., 1992. These colloidal 
dispersions are formed at appropriate ratio of oil, 
water surfactants and cosurfactant. Unlike coarse 
emulsion micronized with external energy 
microemulsion are based on low interfacial 
tension. This is achieved by adding a cosurfactant 
which leads to spontaneous formation of a 
thermodynamically stable microemulsion. The 
droplet size in the dispersed phase is usually 
below 140 nm in diameter, which makes 
microemulsion transparent liquid [9].  
Microemulsions are emulsions producing a 
transparent product that has a very small droplet 
size and does not have tendency to coalesce. A 
large amount of drug can in fact be incorporated 
in these formulations, Due to the high 
solubilising capacity of hydrophobic drugs [10]. 
  
Materials and Methods 
Acyclovir was obtained as gift sample by Cipla 
Ltd, Mumbai. Castor Oil was purchased from 
Loba chemicals, Carbitol, Eucalyptus oils, 
Isopropyl meristate, Methanol, Olive oil, Oleic 
Acid, Propylene glycol, PEG 400, Span 80, 
Tween 80, Triacetin and Tween 20 purchased 
from CDH, Delhi, INDIA. Corbopol934 was 
purchased from CDH, Delhi. Ethanol (Qualigens 
fine chemicals, Mumbai) were obtained from, 
Departmental chemical store of B. U. Jhansi, 
India. All other chemicals used were of analytical 
reagent grade and used as received without 
further purification. Double-distilled water was 
used though out the study. 
Determination of Drug Solubility  
Drug solubility was determined in water by 
dissolving an excess amount of ACV was added 
to distilled water. This suspension was stirred at 
room temperature for 24 h with a magnetic 
stirrer. The sample was then filtered though a 
0.45-μm membrane filter. The concentration of 
ACV was determined spectrophotometrically at 
254 nm.  
To find out suitable oils that have good 
solublizing capacity of ACV as well as ability to 
yield system with larger microemulsion existed 
area, solubility of ACV in various oils (oleic acid 
, olive oil, IPM, castor oil, triacetin, capmul oil 
and combination of these oils) 
surfactants(tween20, tween80, span80) and 
cosurfactants (carbitol, ethanol, propylene glycol, 
PEG400) were determined by dissolving excess 
amount of ACV in 2 ml of each selected oils, 
surfactants and cosurfactnts separately in 5ml 
capacity stoppered vials and mixed by 
continuously  stirred for 72 h. The mixture vials 
were then kept at 37 ± 0.5 °C in an isothermal 
shaker (Jyoti instrument Industry M.P., India) for 
72 h to get equilibrium. Then equilibrated 
samples were removed from shaker and 
centrifuged at 10,000 rpm for 10 min. The 
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supernatant of ACV was separated, filtered and 
after appropriate dilution with methanol, 
solubility was determined by UV 
spectrophotometer at λmax 254 nm. Solubility of 
ACV in oils phase and in surfactant and 
cosurfactant was shown in Table. 1. And Table.2: 
respectively.  
Table.1: Solubility of Acyclovir in different oils. 
S. No. Oils Solubility 
(mg/ml) 
1.   Olive oil 3.48  ± 0.20 
2.   Oleic Acid 9.73  ± 1.50 
3.   Oleic Acid+IPM(1:1) 8.57  ± 2.00 
4.   Oleic Acid+Olive Oil1:1) 3.48  ± 1.00 
5.   Oleic Acid+Castor oil(3:1) 45.53 ±1.50 
6.   Oleic Acid+ Castor oil(1:2) 35.00 ±2.00 
7.   Oleic acid+Castor oil(1:4) 40.53 ±2.10 
8.   OA+OO+Castor oil (1:1:1) 11.28 ±1.00 
9.   Capmul oil 1.37 ±0.50 
10.   Triacetin 0.33 ±0.10 
11.   IPM 1.95 ±0.05 
12.   Castor oil+ IPM(3:1) 3.75 ±2.0 
Table .2: Solubility of Acyclovir in different 
surfactants and cosurfactant  
S.No. Surfactants / 
Cosurfactants 
Solubility 
(mg/ml) 
1.   Tween80 79.0±5.00 
2.   Tween20 1.37±0.50 
3.   Span80 30.00±2.0 
4.   Carbitol 88.21±5.00 
5.   Propylene Glycol 11.28±2.00 
6.   PEG400 3.19±0.50 
7.   Ethanol 92.32±6.20 
Construction of pseudoternary phase 
diagrams 
On the basis of solubility studies, combination of 
oleic acid and castor oil (3:1) was selected as the 
oil phase. Tween 80 and Ethanol were chosen as 
surfactant and cosurfactant respectively on the 
basis of optimization by constructing phase 
diagram and analyzed the result.  Double distilled 
water was used as an aqueous phase.  For the 
determination of existence zone of 
microemulsion, pseudoternary phase diagrams 
were constructed using water aqueous titration 
method. Surfactant and cosurfactant (Smix) were 
mixed in different weight ratios (1:0, 0.5:1, 1:1, 
2:1 and 3:1).  These Smix were chosen in 
increasing concentration of surfactant with 
respect to cosurfactant for detailed study of the 
phase diagrams. 
For each phase diagram, oil and specific Smix 
were mixed well in different ratios. Sixteen 
different combinations of oil and Smix ( 1:9, 1:8, 
1:7, 1:6, 1:5 1:4, 1:3.5, 1:3, 1:2.3, 1:2, 1:1.5 1:1, 
6:4, 7:3, 8:2 and 9:1) were made so that 
maximum ratio could be covered for the study to 
delineate the boundaries of the phases formed 
precisely in the phase diagrams. Slow titration 
with aqueous phase was done for each weight 
ratio of oil and Smix and visual observation was 
used for transparent, clear and easily flowable 
microemulsion. The physical state of 
microemulsion was marked on a pseudo thee 
component phase diagram with one axis 
representing the aqueous phase, one representing 
oil and the third representing a mixture of 
surfactant and cosurfactant. For each Smix ratio 
separate phase diagram was constructed (Fig.1-
5). Pseudoternary phase diagrams were 
constructed with Ternary Phase Diagram 
Software (Chemix School Ver.3.50 software 
USA.) 
 
 
    Figure 1. ME region at Smix=1:0           
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 Figure 2. ME region at Smix=1:1   
 
 
         
  
Figure 3. ME region at Smix=1:2     
 
 
 
 
Figure 4. ME region at Smix=2:1                       
 
 
              Figure 5. ME region at Smix=3:1 
Preparation of Aqueous solution of ACV 
For preparation of aqueous solution of ACV, 5 % 
w/w ACV were weighed and dissolved in 
distilled water for control and having 5 % and 10 
% (w/w). DMSO for comparative studies. Then 
solutions were then filtered with whatmann filter 
paper. 
Preparation of Microemulsion Formulations 
Oil -in- Water (O/ W) liquid microemulsions 
were prepared by dissolving tween80 (surfactant) 
in ethanol (co-surfactant). Mixture of tween80 
and ethanol were then mixed in the mixture oleic 
acid: castor oil (3:1) (oil) followed by gentle 
mixing with double distilled water at room 
temperature until the system was transparent 
under vortexing. The monophasic formulations 
were formed spontaneously at room temperature.  
Formulation of drug loaded microemulsions 
For the preparation of drug loaded 
microemulsions, required amount of Acyclovir 
was dissolved in the oil phase. The required 
amount of mixture of surfactant and cosurfactant 
(in case of cosurfactant) was added and double 
distilled water was then added drop wise drop till 
a clear and transparent liquid was obtained. Then 
added 5 % and 10 % (w/w) DMSO separately. 
The prepared microemulsions were stored in 
tightly in the suitable container at ambient 
temperature. 
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Thermodynamic stability testing of drug loaded 
microemulsions           
To overcome the problem of metastable 
formulation, thermodynamic stability tests were 
performed. Selected formulations loaded with 
drug were centrifuged at 5000 rpm for 30 
minutes. The formulations that did not show any 
phase separations were taken for the heating and 
cooling cycle. Six cycles between refrigerator 
temperature (4ºC) and temperature 45 ºC with 
storage at each temperature of not less than 48 h 
were done. The formulations, which were stable 
at these temperatures, were subjected to a freeze-
thaw cycle test. The freeze thaw cycles were 
done for the formulation between –21ºC and 
25ºC. The formulations that survived 
thermodynamic stability tests were selected for 
further study [11].  
 Determination of droplet shape and size in 
microemulsion 
The surface morphology of microemulsion 
droplets were evaluated by the transmission 
electron microscopy, TEM (Morgangni 268D 
SEI, USA). Operating at 200 KV and capable of 
0.18 nm of point to point resolutions. 
Combination of bright field imaging at increasing 
magnification and of diffraction modes were used 
to reveal the shape and size of the 
microemulsion. In order to perform the TEM 
observation the diluted microemulsion was 
placed on the holey film grid and observed after 
drying.  
The size of oil droplets in microemulsion was 
determined using a Zetasizer ((1000 HS, Malvern 
Instruments, UK) at 25ºC at 23º, 30.1º, 62.5º and 
90º angle. Because intensity of light is angle 
dependent since particles scatter light to different 
angle with different intensities [12]. 
Data analysis 
The cumulative amount of Acyclovir permeated 
though excised rat skin (Q, µg/ cm2) was plotted 
as a function of time. The slope and intercept of 
the linear portion of the plot was derived by 
regression. The permeation rate at steady-state 
(Js, µg/ cm2/h) was calculated as the slope 
divided by the skin surface area. The intercept on 
the X-axis was taken as the lag time (TL, h).      
                                                 
Concentration (µg/ml) × Dilution 
factor 
Cumulative amount of drug permeated = 
                                                                               Skin area (cm2) 
Flux (Js) = slope of the steady state portion of the 
plot between cumulative amount of the drug 
permeated Vs time. (Js, µg/ cm2/h) 
                                                       Js 
Permeability coefficient =                                    
                                                      Cdonor 
Cdonor =   Concentration of drug in donor comportment 
 
Enhancement ratio: 
 ER =   Transdermal flux from Microemulsion 
formulation / Transdermal flux from control  
In-Vitro skin permeation studies 
In-Vitro skin permeation studies were carried out 
using Keshary-Chien Franz diffusion cells (Rama 
Scientific works, Delhi, India) with a diffusional 
surface area of 0.385 cm2 and 5.0 ml of receptor 
cell volume, placed in heating stirring module. 
The full-thickness rat skin was excised from the 
abdominal region, and hair was removed with an 
electric clipper. The subcutaneous tissue was 
removed surgically, and the dermis side was 
wiped with isopropyl alcohol to remove adhering 
fat. The cleaned skin was washed with distilled 
water and stored in the deep freezer at –21°C 
until further use. The skin pieces of wistar albino 
rat [13], were mounted over diffusion cells with 
the dermal-side in contact with receptor phase 
and then air bubbles were removed then 
equilibrated for 2 h. The receptor compartments 
were filled with phosphate buffered saline (PBS) 
pH 7.4, containing 10% w/wof DMSO [14]. The 
receiver fluid was filled in the assembled 
apparatus the Keshary-Chien Franz diffusion and 
stirred with a magnetic stirred at a speed of 600 
rpm, and the temperature maintained at 
37±0.5°C. All the PBS was replaced every 30 
minutes to stabilize the skin. It was found that the 
receiver fluid showed negligible absorbance after 
4.5 hours and beyond, indicating complete 
stabilization of the skin. After complete 
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stabilization of the skin, 3 g microemulsion was 
applied on the skin surface in the donor 
comportment and whole assembly was 
maintained at 37±0.5 °C and magnetically stirred 
at 600 rpm [15].  0.5ml of aliquot was collected 
from the sampling arm from the receptor 
comportment  at designated time intervals (i.e. 0, 
1, 2, 3, 4, 5, 6, 8, 10, 12, and 24 h) for 24 h period 
and  replaced immediately with an equal volume 
of fresh phosphate buffer saline equilibrated at 
37±0.5°C. After appropriate dilution, samples 
were filtered using 0.45µm membrane filter and 
the amount of drug in the receptor fluid was 
analyzed using UV spectrophotometer at λmax 254 
nm. The cumulative amounts of drug permeated 
in µg/cm2 and the percentage of the cumulative 
amount permeated after 24 h were calculated. 
Then flux of every formulation and plain drug 
ACV was calculated and given in the Table 4.  
Statistical Analysis 
The data were analyzed statistically by the 
Repeated Measures Analysis of Variance 
ANOVA test followed by the least significant 
difference procedure. This statistical analysis was 
carried out using GraphPad Prism5.0 Softwares 
(Inc, San Digeo USA), Graphpad InStat 
Softwares (Inc, San Digeo, USA). The data from 
different formulations were compared for 
statistical significance by Repeated Measures 
Analysis of variance (ANOVA) (Dunnet multiple 
comparison test). Differences were considered to 
be statistically significant when P*< .05, P**< 
.01. P***< .001, each set of experiments were 
performed at least three times (n=3). 
Results and Discussion 
Determination of Drug Solubility and 
Construction of pseudo ternary phase 
diagrams 
Selection of an appropriate oily phase is very 
important as it influences the selection of other 
ingredients and microemulsion, mainly in case of 
o/w microemulsion. Usually the oil, which has 
maximum solubilising potential for the selected 
drug candidates, is selected as oily phase for the 
formulation of microemulsion. This help to 
achieve the maximum drug loading in the 
microemulsion. At the same time ability of the 
selected oil to yield system with larger 
microemulsion existed area is also important. It 
is difficult for the single oily component to 
amalgamate both the requirements [16].   
The choice of oily phase is often a compromise 
between its ability to solubilise the drug and to 
facilitate formation of microemulsion of desired 
characteristics. In certain case, mixture of oils is 
also used to meet both requirements. After 
performing solubility study in different oils and 
its combinations, it was found that Acyclovir 
exhibited maximum solubility in mixture of oils 
Oleic acid and Castor oil (3:1) (45.53 mg/ml), 
carbitol (88.21±5.00 mg/ml) and ethanol 
(92.32±6.20 mg/ml) shown in Table 1. Therefore 
Oleic acid:Castor oil (3:1) was chosen as the oil 
phase, carbitol as surfactant and ethanol as 
cosurfactant respectively.  
Screening of surfactants  
Choice of surfactant is critical for the 
formulation of microemulsion. The surfactant 
should favour microemulsification of the oil 
phase and should also possess good solubilising 
potential for the drug. It should be noted that the 
surfactants are not innocuous. The factor must be 
considered while choosing a type & 
concentration of surfactant. Generally, 
surfactants of natural origin are preferred over 
synthetic surfactants. Low HLB surfactant such 
as sorbitan monostearate (HLB, 4.3) are 
preferred for w/o microemulsion where as high 
HLB surfactant such as tween 80 (HLB, 15.0), 
tween 20 (HLB, 16.7) are preferred for o/w 
microemulsion. Taking carbitol as cosurfactant 
different surfactants  ( tween 20, tween 80, span 
80) were titrated with water in sixteen different 
ratios (1:9, 1:8, 1:7, 1:6, 1:5 1:4, 1:3.5, 1:3, 1:2.3, 
1:2, 1:1.5, 1:1, 6:4, 7:3, 8:2 and 9:1) of oil to 
Smix, so that maximum area could be covered for 
the study to delineate the boundaries of the 
phases formed precisely in the phase diagram. 
Slow titration with aqueous phase was done for 
the each weight ratio of oil and Smix and visual 
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observation was used for the transparent, clear 
and easily flowable microemulsion. The physical 
state of microemulsion was marked on a pseudo 
thee component phase diagram with one axis 
representing the aqueous phase, second 
representing oil phase and third representing a 
mixture of surfactant and cosurfactant at fixed 
weight ratio (Smix ratio). On the basis of 
constructed pseudoternary phase diagram using 
tween 80 and carbitol, tween 20 and carbitol and 
span 80 and carbitol, it was clear that 
microemulsion region in the pseudoternary phase 
diagram were decreasing in order respectively, 
because tween 80 had greater oil mixture (oleic 
acid: castor oil) solubilising power than tween 20 
and span 80. It was clear after phase diagram 
study that phase diagram having tween 80 
showed largest microemulsion area, therefore 
tween 80 was selected as surfactant 
Screening of Cosurfactants  
Most of the times, surfactant alone cannot lower 
the oil-water interfacial tension sufficiently to 
yield a microemulsion which was necessities 
addition of an amphiphilic short chain molecules  
or  cosurfactant, bring about the surface tension  
close to zero. Short chain length ranging from C2 
– C10 & amphiphilic nature of these agents 
enables them to interact with surfactant 
monolayer at the interface thereby affecting their 
packing. Liquid crystalline phase are formed 
when the surfactant film is too rigid.  
Cosurfactants penetrate into surfactant monolayer 
providing additional fluidity to interfacial film 
and thus disrupting the liquid crystalline phases. 
Furthermore cosurfactants also distributed 
themselves between aqueous and oily phase, 
thereby altering the chemical composition & 
hence relative hydro/lipophilicity of the system. 
Short chain amphiphilic nature of ethanol enables 
formulation of microemulsion or with a variety 
oily phase and surfactant [17].  Titration was 
done by using tween 80 as surfactant with 
different cosurfactants (Ethanol, Carbitol, 
Propylene Glycol, and PEG 400). The ratio of 
surfactant and cosurfactant were kept constant 
1:1.while oil to Smix ratio was 1:9, 1:8, 1:7, 1:6, 
1:5 1:4, 1:3.5, 1:3, 1:2.3, 1:2, 1:1.5, 1:1, 6:4, 7:3, 
8:2 and 9:1 by considering that the higher 
concentration of surfactant or Smix is favourable 
for maximum microemulsion formation . After 
studying the result of pseudoternary phase 
diagram microemulsion region (covered area), it 
was found that maximum microemulsion region 
or points were obtained with ethanol and hence 
ethanol was chosen as cosurfactant for 
microemulsion formulation. It is advantageous to 
select ethanol as cosurfactant is that ethanol is a 
cosolvent. . 
Preparation of Microemulsion Formulations 
For the preparation of drug loaded 
microemulsions, required amount of Acyclovir 
was dissolved in the oil phase. The required 
amount of mixture of surfactant and cosurfactant 
(in case of cosurfactant) was added and double 
distilled water was then added drop wise drop till 
a clear and transparent liquid was obtained. Then 
added 5% and 10% (w/w) DMSO separately. The 
prepared microemulsions were stored in tightly in 
the suitable container at ambient temperature. 
The composition of aqueous solution of ACV and 
ACV microemulsion without DMSO or with 
DMSO were shown in Table.3. 
Table.3: Compositions of the Selected Microemulsion 
Formulations 
 
 
Thermodynamic stability testing of drug loaded 
microemulsions  
Thermodynamic stability testing was done to 
overcome the problems to identify the deference 
Formul-
ations 
Code 
Oleic acid 
+ Castor 
oil       (3:1) 
(% w/w) 
Tween 80 
+ Ethanol    
(Smix)        
(% w/w) 
Double 
Distilled 
Water 
(%w/w) 
Drug 
(ACV)    
(%w/w) 
DMSO 
(%w/w) 
PD - - 95 5 - 
PD5D - - 90 5 5 
PD10D - - 85 5 10 
ME1 4.96 45.01 50.03 5 - 
ME2 6.12 48.93 44.95 5 - 
ME3 7.49 53.43 40.08 5 - 
ME4 4.55 40.90 54.55 5 - 
ME5 3.51 31.58 64.91 5 - 
ME6 6.67 53.33 40.00 5 - 
ME10D 4.96 45.01 40.03 5 10 
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between stable microemulsions and metastable 
microemulsion. Freeze thaw cycles were done to 
check the stability at low temperature and 
centrifugation studies to check stability at higher 
shear. All microemulsion formulations subjected 
to the above studies should returned to their 
original form when subjected to freeze thaw 
cycle and did not show any sign of turbidity and 
phase separation on high speed centrifugation. 
All selected microemulsions did not show any 
phase separation, turbidity, and change in colour 
& drug precipitation. Selected 
thermodynamically stable microemulsion 
formulations were carried out for further study of 
in-vitro permeation study. 
Determination of droplet shape and size in 
microemulsion 
The surface morphology of microemulsion 
droplets were evaluated by the transmission 
electron microscopy which was shown in the 
Figure.6. Microemulsion was a colloidal 
dispersion .The drug loaded microemulsion oily 
phase droplets shapes were found to be spherical. 
The mean droplet size of oil phase loaded with 
ACV of the optimized microemulsion 
formulation was found to be in range of ME1 
46.29 to 57.10 nm, where as macroemulsion 
droplet size was found to be in range of 659 to 
781nm. The droplet size increased with the 
increase in concentration of oil in the 
formulations [18]. The droplet size was also 
depending on the concentration of Smix, water 
content, viscosity of the microemulsion. Lower 
the viscosity of microemulsion smaller the 
droplet size and this is due to effect of Smix 
because it lower the interfacial tension closed to 
zero, smaller the droplet size containing 
microemulsion have a greater stability and 
transdermal flux. 
The droplet size distribution of microemulsion 
was determined by Malvern Zetasizer(1000 HS, 
Malvern Instruments, UK). The mean size of 
droplet of microemulsion ME1 was shown also in 
Malvern zetasiser size distribution report was 
also found 49.53nm shown in Figure 7. 
 
  
 
Figure 6: TEM image of Microemulsion          
 
Figure 7.Zetasizer droplet size analysis report 
In-Vitro skin permeation studies 
All experiments and protocols described in this 
study were approved by the Institutional Animal 
Ethics Committee of Bundelkhand University, 
Jhansi (Approval No. BU/ Pharm/ IAEC/ 2008/ 
002) and are in accordance with the Committee for 
Purpose of Control and Supervision of 
Experiments on Animals, Ministry of Social 
Justice and Empowerment, Government of India. 
The permeation capability of the selected 
microemulsion formulations and aqueous solution 
of  ACV were evaluated by conducting the in-vitro 
skin permeation experiments with keshary chein 
frenz diffusion cell. The permeation parameters, 
transdermal flux, permeability coefficients and 
cumulative amount of ACV permeated of selected 
microemulsion and control formulations were 
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presented in Table.4 and Figure.8 respectively. The 
transdermal flux of plain ACV  PD  was too less, 
this may be due to large content of drug may have 
substantially reduced the partition coefficient 
between the skin and the vehicle for the drug, 
which can counteract the benefit of the increased 
concentration gradients effect, and thereby actually 
decrease the transdermal  flux [4]. Aqueous 
solution of ACV having 10% DMSO PD10D, 
shown the transdermal flux 119.76 µg/cm2/h which 
was greater than two time more transdermal flux at 
5 % DMSO concentration PD5D 50.75 µg/cm2/h. 
Oleic Acid is advantageous to use as oily phase 
because it increase skin permeability by two 
mechanistic scenarios of the enhancer; (a) lipid 
fluidization, and (b) lipid phase separation [19],  
 
Oleic acid is a model skin permeation enhancer 
[20], Oleic acid facilitates penetration into the skin 
by disrupting the fluidity of the stratum corneum 
[21]. The thermodynamic activity of drug in the 
formulation is a significant driving force for the 
release and penetration of the drug into skin [22]. 
Many different theories concerning the mechanism 
of action of penetrates have appeared in the 
literature. One of them attributes the penetrant 
effects of DMSO, dimethylformamide, and 
dimethylacetamide to their hygroscopic properties. 
Organic solvents like benzene, alcohol, and ether, 
which have been shown to enhance the penetration 
rate of both water-soluble and lipid-soluble 
substances, may act by removing the lipids from 
the stratum corneum. However, the action of 
hydrogen-bonding solvents like DMSO, 
dimethylformamide, and dimethylacetamide is 
attributed to membrane expansion and uniform 
increase in media diffusivity and thus enhances the 
transdermal flux.  The increased flux of 
ME1+10%DMSO (ME10D) was found to be 
266.6721 µg/cm2/h, In comparison with ME1 
(238.1432 µg/cm2/h) (Fig. 9).Which is reported 
that DMSO enhances the transdermal flux of 
poorly water soluble drugs[4]. Short-chain alkanols 
are widely used as permeation enhancers. Ethanol 
is very common among transdermal formulations 
and its addition is known to enhance the flux of 
several drugs. Sometimes when using ethanol- 
water-based vehicles, the effect of ethanol is 
concentration-dependent and therefore, under 
certain conditions it can even decrease the 
permeation. Various mechanisms have been 
suggested for the enhancing activity of ethanol. It 
can increase the drug solubility in the vehicle or it 
can alter the structure of the membrane and 
increase the permeability of the drug. Another 
mechanism is based on the fact that ethanol is 
volatilized from the applied formulation and, 
consequently, increases the drug concentration to a 
supersaturated state with a greater driving force for 
permeation. In addition, ethanol may extract some 
of the lipid fraction from the stratum corneum and, 
thus can improve the drug flux though it [23]. 
Table.4: In-vitro parameters of Aqueous solution of plain drug 
ACV, Aqueous solution of plain drug ACV+5% (w/w) DMSO 
(PD5D), Aqueous solution of plain drug ACV+10% (w/w) 
DMSO (PD10D)  microemulsion (ME), ME+10% (w/w) DMSO 
(ME10D) Formulation. 
 Values are mean ± SD, n=3, P* <0.05, P** <0.001, P*** 
<0.0001, As compared to control (PD), Repeated Measures 
Analysis of Variance ANOVA (Dunnet multiple 
comparison test). 
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Formul- ation 
Code 
Flux  (J)    
(µg/cm2/h) 
Perme-ability 
Coefficient (Kp)  
×10¯2 (cm/ h) 
Enhanceme
nt ratio 
with PD 
PD 2.47±0.76 0.014 -------- 
PD5D 50.7529±1.21 0.203 20.4814 
PD10D 119.7691±5.42*** 0.718 48.3329 
ME1 238.1432±4.82*** 1.428 96.1029 
ME2 127.6±2.82* 0.7656 51.4931 
ME3 110.0 ±4.14*** 0.66 44.3906 
ME4 98.65±3.37** 0.5919 39.8103 
ME5 153.2±4.81*** 0.9192 61.8240 
ME6 90.01±4.26 0.54006 36.3236 
ME10D 266.6721±8.49*** 1.600 107.6159 
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Fig 8. Cumulative amount of ACV permeated from 
microemulsion formulations through rat skin 
Ethanol plays an important role in permeation of 
ACV though rat skin. Ethanol is model penetration 
enhancer. Ethanol can exert its permeation 
enhancing activity though various mechanisms. 
Firstly, as a solvent, it can increase the solubility of 
the drug in the vehicle, although at steady state the 
flux of a permeant from any saturated, non-
enhancing, vehicle should be equivalent. However, 
for poorly soluble permeants that are prone to 
depletion within the donor during a steady state 
permeation study, then ethanol can increase 
permeant solubility in the donor phase [24].Liquid 
crystalline phase are formed when the surfactant 
film is too rigid. Ethanol penetrates into surfactant 
monolayer providing additional fluidity to 
interfacial film and thus disrupting the liquid 
crystalline phases. Furthermore, cosurfactants also 
distributed themselves between aqueous and oily 
phase, thereby altering the chemical composition 
& hence relative hydro/ lipophilicity of the system. 
It has been used to enhance the flux, drug like 
levonorgestrel, estradiol, hydrocortisone and 5-
fluorouracil though rat skin [1]. 
 
   
 Figure 9. Flux of different formulations 
 of the 
teins and on 
 having microemulsion ME10D 
n 
Dimethylsulphoxide (DMSO) is one
earliest and most widely studied penetration 
enhancers. It is a powerful aprotic solvent which 
hydrogen bonds with itself rather than with 
water; it is often used in many areas of 
pharmaceutical sciences as a ‘‘universal 
solvent’’. DMSO is used as a co-solvent in a 
vehicle for a commercial preparation of 
idoxuridine, used to treat severe herpetic 
infections of the skin, particularly those caused 
by herpes simplex. DMSO alone has also been 
applied topically to treat systemic inflammation, 
although currently it is used only to treat animals. 
A vast array of literature describes the 
penetration enhancing activities of DMSO, and 
studies have shown it to be effective in promoting 
both hydrophilic and lipophilic permeants. Thus, 
it has been shown to promote the permeation of, 
for example, antiviral agents, steroids and 
antibiotics. DMSO works rapidly as a penetration 
enhancer-spillage of the material onto the skin 
can be tasted in the mouth within seconds. 
Although DMSO is an excellent accelerant it 
does create problems. The effects of the enhancer 
are concentration dependent. However, at >60% 
relatively high concentrations DMSO can cause 
erythema and wheals of the stratum corneum and 
may denature some proteins. Studies performed 
over40 years ago on healthy volunteers painted 
with 90%DMSO twice daily for 3 weeks resulted 
in erythema, scaling, contact uticaria, stinging 
and burning sensations and several volunteers 
developed systemic symptoms [25]. 
DMSO is widely used to denature pro
application to human skin has been shown to 
change the intercellular keratin confirmation, 
from a helical to β sheet [26, 27]. As well as an 
effect on the proteins, DMSO has also been 
shown to interact with the intercellular lipid 
domains of human stratum corneum. Considering 
the small highly polar nature of this molecule it is 
feasible that DMSO interacts with the head 
groups of some bilayer lipids to distort to the 
packing geometry. Further, DMSO within skin 
membranes may facilitate drug partitioning from 
a formulation into this ‘‘universal solvent’’ 
within the tissue. 
The flux of DMSO
was found 266.6721±8.49µg/cm2/h which showed 
highest value, and significantly very higher than 
the controls (PD & PD10D), the decrease in the 
flux of PD (compared with microemulsion 
ME10D) might be due to change in the water 
content, viscosity of aqueous solution of ACV.  
The skin permeation profile of microemulsio
PD10D, ME1 and ME10D was significantly 
different when compared with that of PD, P* 
<0.05, P** <0.002 and P** <0.002 respectively. 
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n that DMSO and Ethanol acts as a 
owledgement  
l to Director, Institute of 
1 AC, Barry BW. Penetration 
, Iglesias-Vilas G, Blanco-
The significant difference in acyclovir 
permeation between microemulsion formulations, 
PD and ME10D was probably due to the mean 
size of internal phase droplets, which were 
significantly smaller in microemulsions and 
effect of DMSO penetration enhancer. 
Conlusion  
We have show
penetration enhancer for the transdermal delivery 
of ACV and skin flux of the drug could be 
enhanced up to 107 fold compared to its aqueous 
solution. Increased percentage of DMSO 10% as 
compared to 5% in aqueous solution enhanced 
transdermal flux 2.36 fold greater. The skin flux 
of the drug is dependent on the concentration of 
water, DMSO and ethanol in microemulsion. 
Microemulsion is safe to the skin at 10% DMSO 
w/w. 
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